Description: <b>Lignans</b> are a group of polyphenolic compounds found in various plant-based foods, particularly in seeds (especially flaxseeds), whole grains, fruits, and vegetables. They are known for their antioxidant properties and potential health benefits, including their role in cancer prevention.<br>
Phytoestrogens: Lignans are classified as phytoestrogens, which means they can mimic estrogen in the body. This property is particularly relevant in the context of hormone-related cancers, such as breast and prostate cancer. <br>
Antioxidant Activity: Lignans possess antioxidant properties, which can help protect cells from oxidative stress and damage. <br>
Anti-Inflammatory Effects: Some research indicates that lignans may have anti-inflammatory effects, which could be beneficial since chronic inflammation is associated with the development and progression of cancer.<br>
<p><b>Lignans</b> — are a structurally diverse class of plant-derived polyphenolic phenylpropanoid dimers rather than a single compound. Dietary lignans include secoisolariciresinol diglucoside (SDG), secoisolariciresinol (SECO), matairesinol (MAT), pinoresinol and lariciresinol; flaxseed is an especially concentrated dietary source. Intestinal microbiota convert several plant lignans into the mammalian enterolignans enterodiol (END/ED) and enterolactone (ENL/EL), which account for important systemic biological effects. Lignans are formally classified as dietary polyphenols and, particularly after conversion to enterolignans, as phytoestrogens. The Nestronics abbreviation is lign. Their biological effects cannot be generalized to every lignan because molecular targets, potency, metabolism and exposure differ substantially among individual compounds.<br>
-SDG: major flax lignan precursor <br>
</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Estrogen-receptor modulation — enterolactone and enterodiol interact with ERα and ERβ and can produce estrogenic or anti-estrogenic effects depending on concentration, tissue, hormonal environment and receptor context; this is especially relevant to breast and other hormone-responsive cancers.</li>
<li>Suppression of proliferative and survival signaling — selected lignans and enterolignans inhibit proliferative signaling including PI3K/AKT and NF-κB and can reduce Ki-67 and other proliferation-associated signals.</li>
<li>Induction of programmed cancer-cell death — selected lignans, particularly SDG in experimental systems, can promote mitochondrial apoptosis and caspase-dependent cell death; SDG has also induced GSDMD/caspase-1-associated pyroptosis in colorectal cancer models.</li>
<li>Anti-angiogenic activity — enterolactone can suppress VEGF/VEGFR-associated angiogenesis and tumor vascularization; newer preclinical evidence also implicates THBS1/CD36 signaling.</li>
<li>Suppression of invasion and metastasis — enterolignans can modulate MMPs and other migration/invasion pathways, although this evidence remains predominantly preclinical.</li>
<li>Inflammatory signaling suppression — SDG and enterolactone can suppress NF-κB-associated inflammatory signaling and inflammatory cytokine pathways.</li>
<li>ROS modulation — lignans are often antioxidant in normal-cell and nutritional contexts, but SDG can increase ROS in some cancer models sufficiently to inhibit PI3K/AKT and trigger mitochondrial death/pyroptosis; this is compound-, dose- and cell-context-dependent.</li>
<li>Estrogen synthesis modulation — enterolactone is a weak/moderate competitive aromatase inhibitor experimentally, potentially modifying local estrogen availability, although this is not equivalent to pharmacologic aromatase inhibition.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Dietary plant lignans require substantial gastrointestinal processing, and systemic activity often reflects their microbial metabolites rather than the ingested parent compounds. After oral SDG, SECO appears first, followed by END and then ENL; reported human peak concentrations occur approximately 5–7 h, 12–24 h and 24–36 h, respectively, with approximate elimination half-lives of 4.8 h, 9.4 h and 13.2 h. Gut microbiome composition therefore materially affects exposure. Crushing or milling flaxseed increases enterolignan bioavailability compared with intact seed.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Concentration is a major translational limitation. Physiological circulating enterolactone concentrations are generally in the nanomolar-to-low-micromolar range and vary markedly between individuals, whereas some anticancer cell studies use tens to hundreds of micromolar concentrations; for example, an antiproliferative IC50 near 262 µM has been reported in MDA-MB-231 cells. Such high-concentration findings should not be interpreted as directly achievable through ordinary dietary lignan exposure. Importantly, enterolactone at 10 µM has also stimulated proliferation in ERα-positive breast-cancer cells, emphasizing concentration- and receptor-dependent effects.</p>
<p><b>Clinical evidence status:</b> Human evidence exists but does not establish lignans as a cancer treatment. Small randomized presurgical studies of flaxseed have reported reduced tumor proliferation markers in breast and prostate cancer, while a randomized phase IIb trial of purified SDG in high-risk premenopausal women did not significantly improve its primary Ki-67 endpoint versus placebo. Observational studies and meta-analyses associate higher enterolactone exposure with improved outcomes in some populations, particularly postmenopausal breast cancer, but these data cannot establish treatment efficacy. Lignans/SDG therefore remain nutritional or investigational adjuncts rather than approved anticancer therapeutics.</p>
<h3>Lignan Mechanisms in Cancer</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Estrogen receptor signaling</td>
<td>ERα/ERβ modulation ↑ or ↓ (context-dependent)</td>
<td>ERα/ERβ modulation ↑ or ↓ (context-dependent)</td>
<td>R/G</td>
<td>Hormone-responsive transcription and proliferation modulation</td>
<td>Central but bidirectional mechanism. ENL can behave as an ER agonist and can also oppose estradiol-dependent effects. Activity depends on receptor status, tissue, concentration and hormonal environment.</td>
</tr>
<tr>
<td>2</td>
<td>PI3K/AKT survival signaling</td>
<td>↓ (compound-dependent)</td>
<td>↔ or context-dependent</td>
<td>R/G</td>
<td>Reduced survival signaling and increased cell death</td>
<td>Especially demonstrated for SDG in experimental colorectal cancer; should not be generalized quantitatively to all lignans.</td>
</tr>
<tr>
<td>3</td>
<td>NF-κB inflammatory survival signaling</td>
<td>↓</td>
<td>↓ inflammatory activation</td>
<td>R/G</td>
<td>Reduced proliferation and inflammatory signaling</td>
<td>Supported by SDG/ENL experimental models and human prostate-tissue associations.</td>
</tr>
<tr>
<td>4</td>
<td>Mitochondrial apoptosis</td>
<td>↑ BAX and apoptotic signaling (compound-dependent)</td>
<td>↔ or cytoprotective effects (context-dependent)</td>
<td>R/G</td>
<td>Programmed cancer-cell death</td>
<td>Most directly demonstrated for specific lignans rather than the entire lignan class.</td>
</tr>
<tr>
<td>5</td>
<td>ROS-mediated cancer cell death</td>
<td>↑ ROS (dose-dependent)</td>
<td>↓ oxidative stress (context-dependent)</td>
<td>P/R</td>
<td>Oxidative stress can initiate PI3K/AKT suppression and mitochondrial death</td>
<td>Bidirectional redox behavior is important. SDG can be pro-oxidant in cancer models while lignans commonly demonstrate antioxidant activity in non-cancer contexts.</td>
</tr>
<tr>
<td>6</td>
<td>Caspase and gasdermin pyroptosis</td>
<td>↑ caspase-1 and GSDMD cleavage (compound-dependent)</td>
<td>Not established</td>
<td>R/G</td>
<td>Pyroptotic cancer-cell death</td>
<td>Demonstrated for SDG in colorectal cancer models; not a class-wide established effect.</td>
</tr>
<tr>
<td>7</td>
<td>VEGF and tumor angiogenesis</td>
<td>↓ VEGF-associated signaling</td>
<td>↓ pathological angiogenic signaling (context-dependent)</td>
<td>G</td>
<td>Reduced tumor vascularization</td>
<td>ENL and flaxseed lignans have reduced estrogen-stimulated VEGF and angiogenesis in breast-cancer models.</td>
</tr>
<tr>
<td>8</td>
<td>THBS1 and CD36 anti-angiogenic signaling</td>
<td>↑ THBS1-associated suppression</td>
<td>Context-dependent</td>
<td>R/G</td>
<td>Suppression of malignant angiogenesis</td>
<td>Recent ENL ovarian-cancer evidence identifies THBS1-3TSR as a potential molecular interaction; currently preclinical.</td>
</tr>
<tr>
<td>9</td>
<td>Cell cycle and proliferation</td>
<td>↓ Ki-67 and proliferation (context-dependent)</td>
<td>Variable</td>
<td>G</td>
<td>Growth restraint</td>
<td>Supported by experimental models and short presurgical human flaxseed studies, but ERα-positive cells can show opposite responses at some ENL concentrations.</td>
</tr>
<tr>
<td>10</td>
<td>MMP-mediated invasion and migration</td>
<td>↓ MMP activity (context-dependent)</td>
<td>Not established</td>
<td>G</td>
<td>Reduced migration and invasion</td>
<td>Evidence is mainly experimental and particularly associated with enterolignans.</td>
</tr>
<tr>
<td>11</td>
<td>Aromatase and estrogen synthesis</td>
<td>↓ aromatase activity</td>
<td>↓ aromatase activity</td>
<td>R</td>
<td>Reduced estrogen synthesis</td>
<td>ENL is a relatively weak competitive aromatase inhibitor; physiological importance remains uncertain.</td>
</tr>
<tr>
<td>12</td>
<td>Clinical Translation Constraint</td>
<td>High experimental concentrations may not be systemically achievable</td>
<td>Substantial microbiome-dependent variability</td>
<td>G</td>
<td>Limits translation of in-vitro anticancer activity</td>
<td>Lignans are heterogeneous compounds. Parent-lignan absorption, microbial conversion to END/ENL, formulation, food processing, receptor status and menopausal status can materially change biological effects. Clinical efficacy as an anticancer therapy is not established.</td>
</tr>
</tbody>
</table>
<p>P: 0–30 min R: 30 min–3 hr G: >3 hr</p>